The Elephant Slide Method MedTech CEOs Use to Stop Boards From Rewriting the Narrative Mid-Meeting

Key Takeaways

• Most medtech boards don't get confused by bad data, they get confused by missing interpretation, and every board member fills that gap differently.
• The Elephant Slide, from RA Capital's SABER framework, forces CEOs to answer "what does this mean" before the room has a chance to ask.
• In RA Capital's worked example, one sentence, "despite enrollment delays, we're still on track for all three data sets before the Series C with safe margin", changed the entire board dynamic.
• The four questions every Elephant Slide must answer: what is the company trying to prove, what changed since last meeting, do we have cash to reach the next value inflection point, and what does the market believe next.
• The same narrative control skill that wins the boardroom is the one that engineers conviction in the market, it's not a separate competency.

The most dangerous moment in a board meeting is not when bad news appears. It's when nobody knows what the bad news means. Most medtech CEOs go department by department, clinical, regulatory, commercial, finance, and hand the board a stack of separate updates with no map to connect them.

By the time you get to the cash slide, every board member has already built their own interpretation of what the enrollment delay, the missed forecast, or the regulatory timeline means for the company. And those interpretations are not the same.

Watch the full episode on YouTube

Why MedTech Board Meetings Go Wrong Before the First Slide

The problem is not the data. Every board deck I've seen from a medtech founder in the last decade has real data in it, charts, timelines, enrollment numbers, cash projections.

The problem is that the data sits in separate sections, presented by separate functions, with no unified interpretation tying them together. The CEO assumes the board will connect the dots. The board assumes the CEO has already connected them.

Neither assumption is correct.

What happens instead is that every board member starts filling in the gaps based on their own bias, the investor tracking runway, the strategic partner watching competitive positioning, the independent director who's been burned before on exactly this kind of enrollment delay.

None of them is wrong. But none of them is looking at the same animal.

I covered this on a recent episode about the Elephant Slide and RA Capital's SABER framework:

"Management thinks they're giving an enrollment update. The board is thinking about financing risk, forecast credibility, cash runway, all these different things."

That misalignment doesn't come from incompetence. It comes from a structural failure in how the update is delivered. And it has a structural fix.

What the Elephant Slide Is and Where It Comes From

The term comes from RA Capital, one of the most respected life sciences investors in the country. Their SABER guide, a 200-page framework for how to run biotech and biopharma board meetings, includes a concept they call the Elephant Slide.

The name comes from an old parable. A group of blind men encounter an elephant. One touches the leg and thinks it's a tree.

One touches the trunk and thinks it's a snake. One touches the tusk and thinks it's a spear. Each man is touching something real. Nobody is wrong. But nobody understands the whole animal.

That's exactly what happens when a medtech CEO leads with department updates. Clinical is touching one part of the elephant. Finance is touching another. The board is sitting there trying to figure out what animal they're looking at.

The Elephant Slide gives the board the whole picture first, before any department update, so they know what animal they're looking at when you start walking through the parts.

It's a single slide, placed at the very beginning of the pre-read. RA Capital is explicit: start here, not after the clinical update, not after the commercial section. Start with the slide that tells the board the state of the company, what changed, and what milestones you're moving toward.

The Anatomy of an Elephant Slide

RA Capital uses a fictional clinical-stage neuro company called Neo to show how this works in practice.

In the before version, Neo presents a standard enrollment update. The chart shows cumulative patient numbers, an original forecast, an updated forecast with a two-month delay, three of four sites active, a new site added. On paper, it's a clean update. But the board is not thinking about the slide.

One board member is asking: why did we add a new site? Another is asking: what does this mean for the Phase 1B data timing?

Another is asking: when is cash out, and do we still get data before we run out? Another, the most dangerous question in the room, is asking: can I believe this forecast, since you already missed the first one?

RA Capital puts an anxiety meter on the side of that slide. The anxiety is not coming from the data. It's coming from the missing interpretation. The board is trying to understand the so what, and nobody has told them.

In the after version, Neo leads with the Elephant Slide. The headline is a single sentence: Despite program A enrollment delays, we're still on track to get all three data sets before the Series C raise with a safe margin.

I covered this on the same episode:

"That sentence by itself changes the entire board meeting. Now the board knows how to read the slide. Yes, there was a delay. But no, the financing story is not broken. The company still has margin if things slip further."

That one slide connects the enrollment timing, the data readout schedule, the Series C window, the cash balance, and the explanation for the key change. The entire board conversation, in one page.

The Four Questions Your Elephant Slide Must Answer

RA Capital's framework comes down to four questions. Every Elephant Slide should answer all four before the first department update begins.

The first is what the company is trying to prove. Not what it's doing, what it's trying to prove. The distinction matters. Doing is operational. Proving is strategic.

The board needs to know what conviction you're building toward.

The second is what changed since the last meeting. Not the full list of updates, the most strategically significant change. The one that shifts the risk profile, the timeline, or the narrative. Everything else is housekeeping.

The third is whether you have enough cash to reach the next value inflection point. Not whether you have enough cash in general, whether you have enough to reach the specific milestone that changes what investors, physicians, and strategics believe about the company.

The fourth is what the market will believe after that milestone that it doesn't believe today. This is the market engineering layer. Clinical milestones don't automatically create conviction. You have to connect the data to the belief change it's supposed to produce.

I've watched medtech companies hit every internal milestone and still struggle to raise their next round because nobody built the bridge from the evidence to the conviction. I covered why that happens on an episode about the five pillars of market engineering.

What This Means Beyond the Boardroom

There's a direct parallel between how you manage narrative in the boardroom and how you manage narrative in the market.

The CEO who walks into a board meeting without an Elephant Slide is doing the same thing as the commercial team that launches without a medtech commercialization strategy, they're expecting the audience to do the interpretive work that only the person with the full picture can do.

When I was a clinical sales rep at Mazor Robotics, I saw this pattern constantly. The product teams had done the clinical work. The surgeon champions believed in the technology.

But the hospital wasn't buying because nobody had connected the enrollment data to the purchase decision in a way the VAC could follow. That's not a data problem. That's a narrative architecture problem.

Dan Rose, who led LimFlow through a $250M exit to Inari Medical, described the board version of this problem when I interviewed him on an episode about the LimFlow exit. He said:

"You don't want to go to your board being like everything's great, you know, because the fact is everything isn't great. It's never all great. And you want to have very open clear communication with your board about what's working and what's not so they can help you."

The Elephant Slide is what makes that openness productive instead of chaotic. You're not hiding the bad news. You're framing it so the board understands what it means before they have a chance to interpret it the wrong way.

What This Means for MedTech Founders

In my experience working with medtech founders at MarketCraft, the board meeting is often where the CEO's narrative control gets tested most directly. The investor who gave you the term sheet saw your best pitch.

The board member who just sat through a two-hour meeting saw everything, the delays, the missed forecasts, the enrollment numbers that came in lower than projected.

The founders who hold the room are not the ones with the cleanest data. They're the ones who told the board what the data means before the board had a chance to decide for themselves.

Start implementing the Elephant Slide in your next pre-read. One slide. One sentence as the headline. Connect what changed, what it means for your financing timeline, and what the board should understand before they read anything else.

If you want to go deeper, RA Capital's full SABER guide is publicly available, 200 slides of board meeting architecture that translates directly to medtech.

The same skill set that controls the board narrative is the one that builds conviction in the market. That's not a coincidence.

The CEO who can't engineer the boardroom narrative probably can't engineer the market narrative either. And the one who masters both is the one who gets to the exit they planned for.

Frequently Asked Questions

What is the Elephant Slide in a board meeting?

The Elephant Slide is a single slide placed at the start of every board pre-read that shows the whole company picture before any department updates begin.

It comes from RA Capital's SABER framework and answers four questions: what the company is trying to prove, what changed since last meeting, whether there's enough cash to reach the next value inflection point, and what the market will believe after that milestone.

The goal is to give the board context before details so no board member fills in the gaps themselves.

How should a medtech CEO open a board meeting?

Start with the Elephant Slide, not the clinical update, not the finance section, not the executive summary. The first thing the board should see is a single slide that answers the "so what" before they've read a single department update.

That means: headline sentence stating the current strategic position, connecting timeline, cash, and the next milestone in one coherent statement. Everything else, clinical, regulatory, commercial, only makes sense once the board knows what animal they're looking at.

What is the RA Capital SABER framework?

SABER is RA Capital's publicly available guide to board meeting management, designed originally for biotech but directly applicable to medtech. It covers board meeting structure, timing, communication strategy, and what they call the Elephant Slide, the opening context-setting slide that connects operational updates to financing and strategic narrative.

The full deck is available at racap.com/saber. It runs approximately 200 slides and is one of the most detailed board communication frameworks available for pre-commercial life sciences companies.

How do you control the narrative in a board meeting as a medtech CEO?

Answer "what does this mean" before the board has a chance to ask it. That means leading with your interpretation of the company's position, not a summary of what happened, but a statement of what it means for your financing timeline, your next milestone, and the risk profile of the company.

The Elephant Slide formalizes this. Before any department presents, the board has already seen your read of the situation. From that point, you're in control of the frame.

Listen to the Full Episode

This episode is available on The State of MedTech. Watch on YouTube. Subscribe wherever you listen to podcasts.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry.

He works with medtech founders and commercial leaders on market engineering, commercialisation strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.